| Net income | 399M |
| Write-off of impaired assets | 0 |
| Depreciation and amortization | 146M |
| Accounts receivable and prepaid items | |
| Inventories | -8M |
| Accounts payable and accrued liabilities | 18M |
| Decrease (increase) in margin accounts | 1M |
| Other | |
| Cash provided by operating activities | |
| Capital expenditures, net of proceeds on disposals | |
| Payment for acquisition | 0 |
| Cash used for investing activities | |
| Proceeds from borrowings | |
| Payments on debt | |
| Bridge financing costs | |
| Repurchases of common stock | |
| Issuance of common stock | |
| Dividends paid (including to non-controlling interests) | -103M |
| Excess tax benefit on share-based compensation | 0 |
| Cash provided by (used for) financing activities | |
| Effect of foreign exchange rate changes on cash | |
| Increase (decrease) in cash and cash equivalents | 317M |
| Cash and cash equivalents, beginning of period | 434M |
| Cash and cash equivalents, end of period | 751M |